HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Fibrosis (Cirrhosis)

Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Also Known As:
Cirrhosis; Fibroses
Networked: 52099 relevant articles (2735 outcomes, 5648 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Inflammation
2. Fibrosis (Cirrhosis)
3. Hepatocellular Carcinoma (Hepatoma)
4. Infection
5. Liver Cirrhosis (Hepatic Cirrhosis)

Experts

1. Poynard, Thierry: 77 articles (05/2015 - 02/2002)
2. Nobili, Valerio: 69 articles (02/2016 - 01/2004)
3. Lin, Han-Chieh: 68 articles (11/2015 - 01/2002)
4. Zhang, Wei: 63 articles (01/2016 - 04/2002)
5. Distler, Oliver: 62 articles (01/2016 - 10/2005)
6. Li, Jun: 60 articles (01/2016 - 07/2004)
7. Arroyo, Vicente: 59 articles (09/2015 - 01/2002)
8. Distler, Jörg H W: 58 articles (01/2016 - 01/2007)
9. Leask, Andrew: 57 articles (11/2015 - 04/2002)
10. Sanyal, Arun J: 56 articles (11/2015 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Fibrosis:
1. CollagenIBA
2. Bleomycin (Blenoxane)FDA LinkGeneric
3. InterferonsIBA
4. Non-alcoholic Fatty Liver DiseaseIBA
5. Ribavirin (Virazole)FDA LinkGeneric
12/01/2006 - "Thus, (1) patients with genotypes 2 and 3 and severe fibrosis can be treated with low dose of Peg-IFN and ribavirin, (2) this study suggests that patients with genotypes 1, 4 and 5 and high viraemia could receive a standard dose of Peg-IFN associated with ribavirin for 48 weeks, (3) side effects limit the efficacy of the treatment with standard dose of Peg-IFN in patients with genotypes 1, 4 and 5 and low viraemia, (4) more studies are needed for patients with genotype 2 or 3 to define the optimal duration (24 or 48 weeks) in patients with severe fibrosis."
04/24/2010 - "Relapse risk increased in patients with cirrhosis, in those with ribavirin dose reductions and in late responders: more than 65% of patients who cleared the virus between weeks 12 and 24 relapsed following 48 weeks of treatment compared with 10% of those attaining a complete EVR (<15 IU/ml) at treatment week 12 (risk ratio 6.4, 95% confidence interval 2.9-14.4). "
01/01/2008 - "Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis."
08/01/2015 - "Ribavirin is required only for some treatment regimens and may be particularly beneficial in patients with cirrhosis. "
04/01/2000 - "Although current evidence suggests that the combination of ribavirin and IFN-alpha might be more efficacious than IFN alone in increasing the response rate in patients in the advanced fibrotic stage, the efficacy of this regimen for patients with well-compensated HCV-related cirrhosis is still unknown and prospective well-designed studies are urgently needed. "
6. Transforming Growth Factor beta (TGF-beta)IBA
7. Lamivudine (3TC)FDA Link
8. Biological Markers (Surrogate Marker)IBA
9. Messenger RNA (mRNA)IBA
10. Transforming Growth Factor beta1 (TGF beta 1)IBA

Therapies and Procedures

1. Liver Transplantation
2. Transplantation (Transplant Recipients)
3. Transplants (Transplant)
4. Ligation
5. Sclerotherapy